

Definition and Derivation of Baseline Characteristics and Outcomes

Contents

1	Version	2
2	Scope	2
3	Abbreviations	3
4	Data sources.....	3
4.1	Electronic case report forms	3
4.1.1	Main randomisation.....	3
4.1.2	Second randomisation	4
4.1.3	Convalescent plasma safety eCRF	5
4.1.4	Follow-up	5
4.1.5	Non-UK sites.....	5
4.2	Registries and NHS datasets	6
4.2.1	Hospital admissions datasets.....	6
4.2.2	PEDW contains data relating to admissions to NHS hospitals in Wales. The data fields used in the RECOVERY trial are equivalent to those used in SUSAPC and HESAPC Mortality datasets	7
4.2.3	COVID specific datasets	7
4.2.4	Intensive Care Datasets.....	8
4.2.5	Disease specific registries.....	9
5	Baseline characteristics	9
5.1.1	Baseline corticosteroid use	9
5.2	Additional baseline characteristics	10
6	Outcomes	10
6.1	All-cause mortality.....	10
6.1.1	Sources	10
6.1.2	Discrepancies	11
6.2	Cause-specific mortality	11
6.3	Time to discharge	11
6.3.1	Sources	12
6.3.2	Discrepancies	12
6.4	Use and duration of ventilation.....	12
6.4.1	Sources	12

6.4.2	Fact of assisted ventilation.....	12
6.4.3	Duration of invasive mechanical ventilation.....	13
6.5	Major cardiac arrhythmia.....	13
6.5.1	Sources	13
6.6	Renal replacement therapy	13
6.6.1	Sources	14
6.6.2	Discrepancies	14
7	Competeness of Follow-up	14
8	Analysis of outcomes at 6-months	14
8.1	Collection of outcomes at 6-months in the UK.....	14
8.1.1	Use of ventilation	14
8.1.2	Hospital recorded diagnosis.....	15
8.1.3	Total duration of critical and hospital in-patient care.....	15
8.2	Collection of 6-month outcomes outside the UK.....	15
9	Appendix 1: OPCS-4 and ICD-10 codes used to identify assisted ventilation and other outcomes in the linked hospitalisation data	17
10	Appendix 2: Rules for determining start/end of advanced respiratory support days in the critical care datasets	18
11	Appendix 3: Definition of prior RRT for End Stage Renal Disease	20
12	Appendix 4: definitions of discharge and of elective/planned admissions	22
13	Appendix 5: Example hospital recorded diagnoses showing extraction of start and end dates	23

1 Version

Date	Version	Comments
06-Jun-2020	0.1	Initial version
08-Jun-2020	0.2	Minor updates
09-Jun-2020	1.0	First released version
11-Dec-2020	2.0	Update to sections 6.4 (use of assisted ventilation) and 6.6 (use of renal replacement therapy)
06-Jan-2020	3.0	Update to clarify the derivation of outcomes and baseline data for the second randomisation and define complete follow-up
14-April-2022	4.0	Updates to frequency of dataset transfers and additional datasets. Addition of section 8 relating to 6-month outcomes. Addition of appendix 4 to provide detail on discharge outcome

2 Scope

This document describes the definition and derivation of the primary, secondary and other outcomes of the RECOVERY trial for the published trial analyses. It should be read alongside the study protocol which defines the study outcomes briefly, and the Statistical Analysis Plan (SAP) which describes the statistical methods used to analyse these outcomes. The SAP

refers to this document (see Section 2.6.4 Detailed derivation of outcomes) which provides detail on how the outcomes are defined, captured and derived.

Most outcomes have more than one potential source which improves completeness of capture but also will inevitably identify discrepancies between different sources. This document describes the principles for how such discrepancies are resolved; the rules for this were developed blind to results. Further details of the methods are described in the RECOVERY trial internal operating procedure for identifying data discrepancies.

3 Abbreviations

ADDE	Annual District Death Extract
CCDS	Critical Care Dataset
CHESS	COVID-19 Hospitalisation in England Surveillance System
CPAP	Continuous Positive Airway Pressure
CRP	C-reactive protein
ECMO	Extra-corporeal membrane oxygenation
eCRF	Electronic Case Report Form
FCE	Finished Consultant Episode
FU	Follow-up
HESAPC	Hospital Episode Statistics Admitted Patient Care
HFNO	High-flow nasal oxygen
ICD-10	International Classification of Diseases 10 th edition
ICNARC	Intensive Care National Audit and Research Centre
IMV	Invasive mechanical ventilation
NHSCR	NHS Central Register (Scotland)
NIV	Non-invasive ventilation
NRS	National Records of Scotland
ONS	Office for National Statistics (ONS)
OPCS-4	Office of Population Censuses Surveys Classification of Surgical Operations and Procedures 4th revision
PDS	Patient Demographic Service
PEDW	Patient Episode Database for Wales
RRT	Renal replacement therapy
PHE	Public Health England
SAP	Statistical Analysis Plan
SICSAG	Scottish Intensive Care Society Audit Group
SMR	Scottish Morbidity Record
SUSAPC	Secondary Use Service Admitted Patient Care
UKRR	UK Renal Registry
WDS	Welsh Demographic Service
WRRS	Welsh Results Reporting Service

4 Data sources

4.1 Electronic case report forms

4.1.1 Main randomisation

The Randomisation eCRF is completed by hospital staff after patients (or a legal representative) have given consent to participate in the trial. It collects the following participant information:

- Identifiers
 - First name, family name

- NHS number
- Date of birth
- Sex (male/female/unknown)
- Inclusion criteria
 - COVID-19 symptom onset date
 - Date of hospitalisation
- Details of acute illness
 - Requirement for oxygen¹
 - Requirement for ventilatory support (none, continuous positive airway pressure, non-invasive ventilation, high-flow nasal oxygen, invasive mechanical ventilation (IMV) or extra-corporeal membrane oxygenation (ECMO))
 - Latest oxygen saturation
 - Latest C-reactive protein, creatinine and D-dimer measurement (if available)
- Comorbidities
 - Diabetes
 - Heart disease
 - Chronic lung disease
 - Tuberculosis
 - HIV
 - Severe chronic liver disease
 - Severe kidney impairment (eGFR <30 mL/min/1.73m² or on dialysis)
 - Long QT syndrome
 - Pregnancy
- Current treatment
 - Macrolide antibiotics
 - Aspirin or other antiplatelet therapy
 - Warfarin or direct oral anticoagulant
 - Venous thromboembolism prophylaxis (standard or increased dose due to COVID-19)
 - Remdesivir
 - Systemic corticosteroids
- Other
 - Weight (children only)

4.1.2 Second randomisation

The Second Randomisation eCRF is completed by hospital staff when they wish to randomise participants between tocilizumab or standard care alone if they fulfil the protocol-defined oxygenation and inflammation criteria. It collects the following participant information:

¹ NHS England advice published on 9 April 2020 stated that the usual oxygen target saturation for prescribed oxygen should change from 94-98% to 92-96% in the first instance. Hospitals may further reduce this to 90-94% if clinically appropriate according to prevailing oxygen demands. <https://www.england.nhs.uk/coronavirus/wp-content/uploads/sites/52/2020/04/C0256-specialty-guide-oxygen-therapy-and-coronavirus-9-april-2020.pdf>. Guidance on admission to hospital was similar in Scotland. <https://www.nhs.uk/media/259232/covid-19-gps-national-supporting-guidance-for-scottish-general-practice.pdf> although hospital guidelines in Scotland did not specify a target oxygen saturation.

- Inclusion criteria
 - Requirement for oxygen
 - Current level of ventilation support (none/CPAP/NIV/HFNO/IMV/ECMO)
 - Latest CRP
- Other information
 - Latest ferritin and creatinine

4.1.3 Convalescent plasma safety eCRF

This eCRF is completed by hospital staff as soon as possible after 72 hours post-main randomisation for participants who entered the convalescent plasma comparison. It collects the following information:

- Adherence to convalescent plasma allocation (number of units received, whether any were stopped early)
- Adverse events
 - Sudden worsening of respiratory status
 - Severe allergic reaction
 - Temperature $\geq 39^{\circ}\text{C}$ (or rise $\geq 2^{\circ}\text{C}$ above baseline)
 - Sudden hypotension
 - Clinical haemolysis
 - Thrombotic event

4.1.4 Follow-up

The FU eCRF is completed by hospital staff at the earliest of (i) discharge from acute care (see Section 6.3 below), (ii) death, or (iii) 28 days after the main randomisation. It collects the following information from date of randomisation onwards:

- Adherence to randomised allocation, and receipt of other study treatments or relevant therapies (and number of days of treatment)
- Vital status and underlying cause of death (COVID, other infection, cardiovascular, other; if other, a free text description is collected)
- Date of discharge
- Requirement for assisted ventilation (CPAP, NIV, HFNO, IMV, ECMO) and number of days of assisted ventilation and IMV/ECMO separately
- Occurrence of major cardiac arrhythmia (atrial flutter/fibrillation, supraventricular tachycardia, ventricular tachycardia [including torsades de pointes], ventricular fibrillation or bradycardia requiring intervention) (from 12 May 2020)
- Occurrence of thrombotic event (pulmonary embolism; deep-vein thrombosis; ischaemic stroke; myocardial infarction; systemic arterial embolism; other) (from 6 November 2020)
- Occurrence of clinically-significant bleeding i.e. intracranial or requiring intervention (blood transfusion; surgery; endoscopy; vasoactive drug or blood transfusion), by site (intra-cranial; gastrointestinal; other) (from 6 November 2020)
- Requirement for renal replacement therapy and peak creatinine after randomisation
- Other infections after randomisation (by site and by organism type)
- Metabolic complications (ketoacidosis, hyperglycaemia, hypoglycaemia)

4.1.5 Non-UK sites

Whereas in the UK participants will be followed by linkage with routinely collected data (see Section 4.2) for up to 10 years after randomisation, in other countries this is not possible. Sites will be asked to complete an additional case report form for participants discharged

alive from hospital at 28 days after randomisation to confirm vital status (and date and cause of death if relevant).

4.2 Registries and NHS datasets

4.2.1 Hospital admissions datasets

4.2.1.1 *Secondary Use Service Admitted Patient Care*

The SUSAPC dataset is a repository of data hosted by NHS Digital that relates to in-patient care provided in England, which aims to enable reporting and analyses to support the NHS in the delivery of healthcare services. These data are submitted on a regular basis by NHS hospital trusts and at pre-arranged dates during the year. Submissions are consolidated, validated and cleaned and then incorporated into the HESAPC dataset. Data may be incomplete in places and is not quality assured to the same extent as HES, but is available more rapidly.

In the SUSAPC dataset, each record contains data relating to a continuous period of care under one consultant known as a Finished Consultant Episode (FCE). FCEs can be grouped together to form 'Spells'. Each spell is a continuous periods of inpatient care within one hospital. Each FCE contains data about the patient (e.g. sex, ethnicity), the specialty providing the care (e.g. cardiology), ICD-10 diagnostic and OPCS-4 procedure codes, along with dates for each procedure and details about the admission and discharge and other data.

For the main RECOVERY analyses the following data are used;

- Admission method (which indicates whether the admission was emergency or elective and whether it involved a transfer from another healthcare provider)
- Admission source (used to identify transfers between hospitals)
- Ethnicity
- Sex
- Date of admission and discharge
- Start and end date of the FCE
- Discharge method and destination (which may indicate death of participant)
- Diagnoses recorded during FCE (ICD-10 coded)
- Procedures performed during FCE (OPCS-4 coded) and corresponding dates

Linked SUSAPC data are imported to the RECOVERY trial database approximately monthly.

4.2.1.2 *Hospital Episode Statistics Admitted Patient Care*

HESAPC contains data relating to admissions to NHS hospitals in England and is produced from the SUSAPC following a number of cleaning and validation steps. For participants in England, HESAPC is available for the 5 year period prior to enrolment in the study. For the main RECOVERY analyses these data are used to identify prior medical conditions on the basis of recorded ICD-10 and OPCS-4 codes (excluding the admission during which the patient was randomised). For the analysis of 6-month outcomes, these data are used to identify the Hospital Recorded Diagnoses (see section 8). Linked HESAPC data are imported to the RECOVERY trial database quarterly.

4.2.1.3 *NHS Central Register Scottish Morbidity Record One*

The NHSCR SMR01 data set holds episode level data on hospital inpatient and day case discharges from acute specialities from hospitals in Scotland. The data fields used in the RECOVERY trial are equivalent to those used in SUSAPC and HESAPC. Linked NHSCR-SMR01 data are imported approximately monthly.

4.2.1.4 Patient Episode Data Wales

4.2.2 PEDW contains data relating to admissions to NHS hospitals in Wales. The data fields used in the RECOVERY trial are equivalent to those used in SUSAPC and HESAPC Mortality datasets

4.2.2.1 Patient Demographic Service

The PDS is the electronic database of NHS patient details such as name, address, date of birth and NHS Number for patients in England. For RECOVERY it is used to provide information on fact and date of death. It provides both 'informal' notifications of death (which occur when a health care provider is informed of their patients death and records the reported date of death in their electronic data systems) and 'formal' notifications of death (which are provided by the Office for National Statistics).

4.2.2.2 Office for National Statistics Mortality data

The ONS mortality data contains information related to a person's death taken from the death certificate for all deaths registered in England and Wales. The following data are provided

- The underlying cause of death
- Contributory causes of death
- Other conditions recorded on the death certificate but not contributing to death
- Whether a post-mortem took place

Clinical data are recorded using ICD-10 codes. Linked ONS mortality data are imported into the RECOVERY trial via a quarterly extract from NHS Digital.

4.2.2.3 Welsh Demographic Service

WDS data are the electronic database of NHS patient details for patients in Wales and are similar to PDS (4.2.2), providing fact and date of death (including formal or informal notifications). Linked data for RECOVERY participants recruited via sites in Wales will be available for future analysis.

4.2.2.4 National Records of Scotland Mortality Data

The NRS mortality data contain information related to a person's death taken from the death certificate for all deaths registered in Scotland. The data provided includes the date of death and the underlying and contributory causes of death coded in ICD-10. Linked data are imported into the RECOVERY trial database approximately monthly.

4.2.3 COVID specific datasets

4.2.3.1 Public Health England Second Generation Surveillance data

The SGSS is an application that captures, stores and manages routine laboratory surveillance data on infectious diseases and antimicrobial resistance from laboratories across England. Once the reports have been loaded into SGSS, each record is subject to a number of validation processes, and local LIMS codes are translated to SGSS codes to standardise the data for analysis. The data is stored in a central database within PHE and details of tests indicating SAR-CoV-2 have been made available to NHS Digital for dissemination for a limited time period. For each test, the following data are available

- Date the sample was collected
- Date the result was reported
- Organism identified (only SARS-CoV-2)

Linked PHE SGSS data are imported into the RECOVERY trial approximately monthly.

4.2.3.2 Public Health Scotland COVID-19 laboratory antigen test positive list

The Electronic Communication of Surveillance in Scotland (ECOSS) collects routine laboratory surveillance data on infectious diseases from laboratories in Scotland. The data provided to RECOVERY is limited to SARS-CoV-2 results along with the date of the sample and result.

4.2.3.3 Welsh Results Reporting Service Pathology Data

The WRRS contains all Pathology Test Results for Wales in a single database. Tests indicating a positive SAR-CoV-2 antigen linked to the trial participants are obtained.

4.2.3.4 COVID-19 Hospitalisation in England Surveillance System

PHE has established the COVID-19 Hospitalisation in England Surveillance System (CHES), which collects epidemiological data (demographics, risk factors, clinical information on severity, and outcome) on COVID-19 infection in patients requiring hospitalisation and ICU/HDU level care. This dataset has been made available to NHS Digital for dissemination for a limited time period. For RECOVERY the following information is used;

- Date of ICU/HDU admission and discharge
- Use of respiratory support during the admission (including oxygen via cannulae or mask, high flow nasal oxygen, non-invasive ventilation, invasive mechanical ventilation and ECMO)
- Complications during the admission (including viral pneumonia, secondary bacterial pneumonia, ARDS, unknown, and other co-infections)

The CHES dataset is imported into the RECOVERY trial approximately monthly.

4.2.3.5 GPES Data for Pandemic Planning and Research (COVID-19) (GDPPR)

GDPPR data is available for RECOVERY participants in England. Data includes patient demographic information and coded medical information (mainly in SNOMED codes).

4.2.4 Intensive Care Datasets

4.2.4.1 Intensive Care National Audit and Research Centre

The ICNARC Case Mix Programme is the national clinical audit covering all NHS adult, general intensive care and combined intensive care/high dependency units in England, Wales and Northern Ireland, plus some additional specialist and non-NHS critical care units. Data are collected about the first 24 hours in ICU/HDU and at discharge from the ICU/HDU with a further data collection point after discharge from hospital. For RECOVERY, the following data recorded at discharge from ICU/HDU are used:

- Date of admission to and discharge from ICU/HDU
- Use of Advanced Respiratory Support (ARS), Basic Respiratory Support (BRS) or Renal Support during the admission
- The number of days of ARS, BRS or Renal Support during the admission
- Date of death (if relevant)

Linked ICNARC data is requested for hospitals recruiting to RECOVERY and are imported approximately monthly.

4.2.4.2 Scottish Intensive Care Society Audit Group

SICSAG collects data from all general adult Intensive Care Units, Combined Units and the majority of High Dependency Units in Scotland using the WardWatcher system. The following data are used in the RECOVERY trial:

- Date of admission and discharge from ICU/HDU

- Used of mechanical ventilation via endotracheal tube or tracheostomy and use of haemofiltration for each day of during admission

Linked SICSAG data are imported into the RECOVERY trial approximately monthly.

4.2.4.3 Critical Care dataset

In England and Wales much of the key data collected by ICNARC is also available in the CCDS from NHS Digital or the SAIL datalink Wales. However, both the ICNARC and CCDS data can be subject to different delays during collection, consolidation and dissemination and therefore either source may be incomplete at any one time-point. Both sources are therefore combined to provide information about ICU/HDU care for participants in England and Wales.

4.2.5 Disease specific registries

4.2.5.1 UK Renal Registry

The UK Renal Registry collates data from renal units and hospital laboratories in all four nations in the UK. Linked data relating to laboratory tests for patients who trigger a hospital laboratory “acute kidney injury alert” are available for a subset of patients. Data relating to the provision of care for end stage kidney disease discuss is provided to RECOVERY on an annual basis.

5 Baseline characteristics

Baseline characteristics for the trial cohort are obtained from the first randomisation eCRF for the main randomisation comparisons. For the second randomisation comparisons, the baseline data are obtained either from the second randomisation form directly (e.g. baseline use of respiratory support) or from a calculation based on the first randomisation form data and the number of days between the first and second randomisation forms (e.g. days since symptom onset).

Where fields are missing, they may be supplemented by data from the linked health care data. Generally corrections to the randomisation eCRF data are not made. Exceptions to this would include key participant identifiers (Date of birth, NHS or CHI number) or cases where information is missing. For example, if a site later report that the date of birth was entered incorrectly, this would be confirmed with the site (recorded in the trial data query system) and updated (with appropriate audit trail).

5.1.1 Baseline corticosteroid use

Baseline steroid use is determined as follows:

- Baseline steroid use = yes if allocated dexamethasone in main randomisation OR responded ‘yes’ to baseline steroid question on main randomisation form (OR [for tocilizumab comparison only] responded ‘yes’ to baseline steroid question on second randomisation form
- Otherwise, Baseline steroid use = no if answered ‘no’ to steroid question on main OR [for tocilizumab comparison only] second randomisation forms
- Otherwise, Baseline steroid use = not asked if recruited prior to June 18th²
- Otherwise, Baseline steroid use = unknown

² From 18th June onwards a question on baseline systemic corticosteroid use was added to the main randomisation form following the release of the dexamethasone comparison results.

For the purposes of analysis, baseline steroid use = no and not asked will be combined for subgroup analyses. Participants with baseline steroid use = unknown will be excluded from subgroup analysis, but the number in this subgroup provided in a footnote.

5.2 Additional baseline characteristics

Some baseline characteristics that are not collected on the randomisation eCRF may be extracted from registry data or other sources. These include:

- Ethnicity by Office for National Statistics 2001 census categories (White, BAME [Mixed, Asian or Asian British, Black or Black British, Other Ethnic Groups], Unknown) from linked health care records. Ethnic groups characterised using SNOMED codes within the GDPPR data are mapped to these categories. Where ethnicity records are discrepant between individual episodes in HES/SMR01/PEDW, the most frequently recorded code is used. Within the GDPPR dataset ethnicity is recorded in two places, the ethnic field in the patient table and the presence of a relevant SNOMED code in the journals table. The most recent code in the journals table is used, where available, otherwise the code from the patient table is used. Where there is discrepancy between the best estimate from GDPPR and HES/SMR01/PEDW existsthe GDPPR code is used. Where neither are available the most frequent fode in the SUS data is used. Individual SNOMED codes are categorised as defined with the SNOMED hierarchy and ethnicity categorieese according to the UK department of health categories.³
- Confirmed SARS-CoV-2 diagnostic test from linked health care records. A positive SARS-CoV-2 with a test date within 28 days of the date of first randomisation is considered as confirmed SARS-CoV-2. In the absence of such data for a participant, the data from the randomisation eCRF may be used.
- Comorbidity score: It is possible to calculate comorbidity and frailty scores (e.g. Charlston Comorbidity Score) from prior linked hospital admissions data and this will be done for future exploratory analyses (not specified in the trial SAP).
- Prior End Stage Kidney Disease (see section 6.6)
- Risk: The risk of death by 28 days can be modelled using available baseline characteristics (in the overall trial population) and a risk score derived. Participants will be divided into thirds based on this score (such that each third has approximately the same number of deaths), with the tertiles rounded to clinically-relevant values. For the main trial analyses the groups will defined as risk of death by 28 days of <30%; ≥30 ≤45%; and >45%.

6 Outcomes

6.1 All-cause mortality

The primary outcome is all-cause mortality at 28 days after randomisation. All-cause mortality will also be assessed at 6 months and other later time points.

6.1.1 Sources

Information on death may come from the following sources:

- FU eCRF (for deaths within first 28 days after randomisation)
- PDS (for participants in England)
- PDS Wales ((or participants in Wales)
- SUSAPC (for participants in England)

³ <https://www.ethnicity-facts-figures.service.gov.uk/style-guide/ethnic-groups>

- SMR01 (for participants in Scotland)
- PEDW (for participants in Wales)
- ONS mortality data (for participants in England and Wales)
- NRS mortality data (for participants in Scotland)

In general, the primary source will be considered ONS (which includes formal death notification within PDS) and NRS mortality data as these are the official national death registries.

6.1.2 Discrepancies

6.1.2.1 *Fact of death*

The ONS and NRS mortality data will be considered the defining source for fact of death. In order to allow rapid analysis of results, other sources (e.g. informal death notification via PDS, report of death on the FU eCRF, report of death from SUSAPC) are used for DMC and interim analyses. Cases where these reports are not later substantiated by ONS or NRS are individually reviewed and are not considered as deaths, unless a suitable explanation exists.

6.1.2.2 *Date of death*

The ONS and NRS data will be considered the defining source for date of death. In order to allow rapid analysis of data, other sources may be used. Where data sources are discrepant the following hierarchy is applied;

- ONS/NRS (most reliable for date of death), then
- Linked hospital admissions data, then
- FU eCRF , then
- PDS informal death notification (least reliable for date of death)

6.2 Cause-specific mortality

The cause of death for the 28 day analysis will be the underlying cause of death as provided by ONS. The causes of death will be categorised as follows:

- Non-vascular death
 - Death from infection
 - Death from COVID-19
 - Death from other infection
 - Death from cancer
 - Death from other medical causes
 - External deaths
- Vascular death
 - Cardiac death
 - Stroke death
 - Other vascular death
- Unknown death

The ICD-10 codes contributing to these categories are available to download from the RECOVERY website.

6.3 Time to discharge

Time to discharge (which is a more accurate term for duration of admission because only the period from randomisation onwards is relevant) is defined as the number of days a participant remained in hospital for acute care after randomisation. Discharge excludes transfer to

another acute hospital, but might include transfer to community hospital for rehabilitation or a hospice for end-of-life care.

6.3.1 Sources

Information on date of discharge may come from the following sources:

- FU eCRF
- SUSAPC (for participants in England)
- PEDW (for participants in Wales)
- SMR01 (for participants in Scotland)

The participant is considered to have been discharged from hospital if there is a discharge date recorded with a discharge method and destination which do not indicate that the participant died or was transferred (see appendix 4). In addition there must be no other admission with an admission date up to 4 days before or 1 day after the discharge date where either the method or source of the admission recorded suggest transfer from another hospital (see appendix 4). The first date of discharge which fulfils these criteria after first or second randomisation is used to determine time to discharge.

6.3.2 Discrepancies

Linked hospital admissions data will be used if date of discharge is discrepant with FU eCRF data. If no linked hospital admissions data are available and the FU eCRF indicates discharge without a date, the date of completion for the FU eCRF will be used.

6.4 Use and duration of ventilation

Assisted ventilation can be broadly divided into

- i. Invasive mechanical ventilation (IMV) which includes ECMO (a secondary outcome in combination with all-cause mortality)
- ii. Non-invasive ventilation which includes CPAP, NIV and HFNO (which are included in the subsidiary outcomes)

Information on non-invasive ventilation was collected because at the time the trial was designed there were concerns that the availability of mechanical ventilators would be insufficient to meet demand, so some patients would be treated with non-invasive ventilation when in other circumstances they would have received invasive mechanical ventilation. In reality this situation did not occur, so the emphasis of the analyses (and efforts to resolve discrepancies) is on invasive mechanical ventilation.

6.4.1 Sources

Information on ventilation may come from the following sources:

- FU eCRF
- SUSAPC/SMR01/PEDW
- ICNARC
- SICSAG
- CHES
- CCDS

However, the coding of ventilation is different in each source.

6.4.2 Fact of assisted ventilation

A participant is considered to have received IMV/ECMO if use of these treatments was recorded on the FU eCRF; if a relevant procedure code was recorded in

SUSAPC/SMR01/PEDW within 28 days of randomisation (Appendix 1); if days of advanced respiratory support (ARS) in the ICNARC/CCDS data were considered to fall between randomisation and 28 days (see section 6.4.3) or if the daily SICSAG record indicated that the participant was receiving respiratory support via an endotracheal tube or tracheostomy.

A participant is considered to have received non-invasive ventilation if the site recorded 'yes' to the question 'did the participant receive assisted ventilation' or 'yes' to any of the individual types of non-invasive ventilation (CPAP, BIPAP, HFNO) on the FU eCRF; if a relevant procedure code was recorded in SUSAPC/SMR01/PEDW within 28 days of randomisation (Appendix 2) or if use of HFNO or NIV was recorded in CHESS when the admission and discharge date were both between randomisation and 28 days.

6.4.3 Duration of invasive mechanical ventilation

The data from the critical care datasets (ICNARC, CCDS and SICSAG) are considered the primary source of the duration of IMV. Within ICNARC/CCDS, ARS is considered to be equivalent to IMV, however only the dates of admission and discharge from ICU/HDU and the number of days of ARS are provided. The days of ARS within each critical care episode are assumed to be continuous. The days of ARS were assumed to include randomisation if the participant was recorded as receiving IMV at baseline on the first or second randomisation eCRF as appropriate. Otherwise, the days of ARS are assumed to start from admission to critical care, occur at the mid-point of the critical care admission or end on discharge from critical care depending on the level of care recorded on admission and discharge and, in some cases, the destination on discharge (Appendix 2). Using these assumptions, the information from both ICNARC and the CCDS were used to identify whether IMV was received on each of the 28 days following randomisation. The SICSAG daily record indicated use of IMV on each day.

If no relevant information on IMV is received from ICNARC/CCDS/SICSAG, then the duration of IMV was obtained from the FU eCRF. Cessation of mechanical ventilation is deemed successful if it occurs within (and the participant survives until) 28 days after randomisation.

6.5 Major cardiac arrhythmia

Major cardiac arrhythmias are defined as either:

- i. Atrial flutter or fibrillation
- ii. Supraventricular tachycardia
- iii. Ventricular tachycardia (including torsades de pointes)
- iv. Ventricular fibrillation
- v. Significant bradycardia (requiring intervention)

6.5.1 Sources

Information on cardiac arrhythmias is collected on the FU eCRF (but only for those eCRFs completed from 12 May 2020 onwards when these outcomes were added).

6.6 Renal replacement therapy

Renal replacement therapy (RRT) includes haemodialysis, haemofiltration (and their combination) and peritoneal dialysis. (Kidney transplantation is not relevant in this case.) Individuals receiving RRT at baseline are identified as follows;

- Patients already receiving renal replacement for End Stage Kidney Disease at baseline are identified using linked hospitalisation data (appendix 3).

- From the ICNARC/CCDS data, the combination of the number of Renal Support Days and the start and end date of a critical episode may imply that they must have been receiving renal support at randomisation.
- The SICSAG daily record indicates that Renal Support was received on the day of, or on the day before randomisation.
- A procedure code in SUS/SMR01/PEDW indicating dialysis or haemofiltration with a date within the 3 days prior to first or second randomisation as appropriate (appendix 1).
- (When available) A record of prior RRT (without documented recovery) from the UK Renal Registry

6.6.1 Sources

- FU eCRF
- Linked hospitalisation data (SUSAPC, HES, PEDW, SMR01)
- ICNARC
- SICSAG
- UKRR

6.6.2 Discrepancies

Use of RRT is collected on the FU eCRF. Use of RRT is also identified within the linked hospitalisation data from relevant OPCS-4 codes (Appendix 1). Use of RRT in the ICNARC/CCDS is identified from the recording of Renal Support days where the both the date of admission to and discharge from critical care fall between randomisation and 28 days. The SICSAG daily record indicates RRT if Renal Support is recorded on any day between randomisation and 28 days.

Further information on renal outcomes may become available from the UK Renal Registry data.

7 Competeness of Follow-up

For the 28 day analysis, follow-up information is considered to be complete if a FU eCRF has been completed, or data has been received from a hospital admissions dataset (SUSAPC, PEDW or SMR01) which includes data from the admission during which the participant was randomised.

8 Analysis of outcomes at 6-months

8.1 Collection of outcomes at 6-months in the UK

In the UK, outcome collection after the initial 28-day follow-up is undertaken by linkage to the routine healthcare datasets, with no further eCRF completion by the site staff. Unless indicated below, the outcomes analysed at 6-months are derived in the same way as for the main trial analyses described in section 6.

8.1.1 Use of ventilation

For the analysis of outcomes at 6-months, use of ventilation is defined in the same way as described in section 6.4. However, periods of ventilation during an elective (i.e. planned) admission following the index admission are excluded, since such procedures are likely to be related to elective surgery rather than complications of COVID-19. Dates of subsequent admissions are obtained from HESAPC and categorised into elective admission or non-

elective admission (including emergency admissions and transfers) on the basis of recorded the admission method (see Appendix 4).

8.1.2 Hospital recorded diagnosis

Diagnoses recorded as the primary reason for a period of in-hospital care are extracted from HESAPC, SMR01 and PEDW. Diagnostic codes are restricted to the first diagnostic position and ICD-10 codes in other positions are not considered. ICD-10 codes within the same block (e.g. I25.1 and I25.2) are considered to relate to the same hospital recorded diagnosis. For each hospital spell the first ICD-10 code recorded within the relevant block is extracted along with a start and end date. The start date is defined as the start of the first episode in which an ICD-10 code in the relevant block is recorded within that spell. The end date is defined as the end of the episode in which an ICD-10 code in the relevant block is recorded within that spell. Examples showing how the dates are extracted are shown in Appendix 5.

Diagnoses for which the first record in that spell is in an episode which started after randomisation are considered to be post-randomisation. Only post-randomisation diagnoses are to be used for the analyses.

Caution should be applied when considering absolute event rates derived from the hospital recorded diagnosis. As can be seen from example 1 and 3 in Appendix 5, more than one hospital recorded diagnoses could be derived from one clinical event, where ICD-10 codes from different blocks are used to record the same clinical event in subsequent episodes. While this is unlikely to result in bias when assessing the proportional effects of treatment, the absolute number of hospital recorded diagnoses should not be interpreted as the absolute number of serious adverse events.

8.1.3 Total duration of critical and hospital in-patient care

Total duration of hospital in-patient care during the 6-months after randomisation is derived from HESAPC based on admission and discharge dates. This is categorised separately by elective vs non-elective (including transfers) as defined in Appendix 4. The total duration of critical care during the 6-months after randomisation is derived from the dates of admission to and discharge from critical care in ICNARC, SUSCCDS, PEDWCCDS and SICSAG. If a period of critical care exists in any of these datasets it will contribute days to this outcome.

8.2 Collection of 6-month outcomes outside the UK

Sites will complete a case report form at 6 months after randomisation to capture information on vital status, use of ventilation and any admissions to hospital.

9 Appendix 1: OPCS-4 and ICD-10 codes used to identify assisted ventilation and other outcomes in the linked hospitalisation data

Outcome	code	Code type	Description
Use of CPAP	E85.6	OPCS	Continuous positive airway pressure
Use of NIV	E85.2	OPCS	Non-invasive ventilation NEC
Use IMV	E85.1	OPCS	Invasive ventilation
Use of ECMO	X58.1	OPCS	Extracorporeal membrane oxygenation
Use of RRT	X40.1	OPCS	Renal dialysis
	X40.3	OPCS	Haemodialysis NEC
	X40.4	OPCS	Haemofiltration

(OPCS and ICD-10 codes used to identify serious arrhythmia and other non-fatal outcomes to be added at a later date.)

10 Appendix: 2: Rules for determining start/end of advanced respiratory support days in the critical care datasets

Information is available in ICNARC/CCDS on

- The start and end date of the critical care episode
- The level of care at admission to the unit
- The level of care at discharge from the unit
- The reason for discharge from the unit
- The number of days of Advance Respiratory Support (ARS) received during the episode

The table below defines the rules for deciding whether the days on ARS in an ICNARC/CCDS episode should count from admission onwards (A), before discharge (D) or at the midpoint between admission and discharge (M)

		Level of care at admission to the unit					blank
		0	1	2	3	blank	
Level of care at discharge from the unit	0	M	M	M	A	A	
	1	M	M	M	A	A	
	2	M	M	M	A	A	
	3	D	D	D	A	D	
	blank	*	*	*	A	A	

* If the reason for discharge from the unit is 'comparable critical care' or 'more-specialist critical care' then D, otherwise M.

The following definitions are taken from the ICNARC data collection manual Version 3.1 (29 June 2009).

Level 3 – indicated by one or more of the following:

- admissions receiving advanced respiratory monitoring and support due to an acute illness
- admissions receiving monitoring and support for two or more organ system dysfunctions (excluding gastrointestinal support) due to an acute illness
- admissions solely receiving basic respiratory monitoring and support and basic cardiovascular monitoring and support due to an acute illness only meet Level 2

Level 2 – indicated by one or more of the following:

- admissions receiving monitoring and support for one organ system dysfunction (excluding gastrointestinal support) due to an acute illness
- admissions solely receiving advanced respiratory monitoring and support due to an acute illness meet Level 3
- admissions solely receiving basic respiratory and basic cardiovascular monitoring and support due to an acute illness meet Level 2
- admissions receiving pre-surgical optimisation including invasive monitoring and treatment to improve organ system function
- admissions receiving extended post-surgical care either because of the procedure and/or the condition of the admission
- admissions stepping down to Level 2 from Level 3 care

Level 1 – indicated by one or more of the following:

- admission recently discharged from a higher level of care
- admissions receiving a greater degree of observation, monitoring, intervention(s), clinical input or advice than Level 0 care
- admissions receiving critical care outreach service support fulfilling the medium-score group, or higher, as defined by NICE Guidelines 50

Level 0 – indicated by the following:

- admissions in hospital and receiving normal ward care

11 Appendix 3: Definition of prior RRT for End Stage Renal Disease

A previously validated algorithm was adapted to identify people requiring dialysis for ESRD from the prior HES/SMR01/PEDW.

Individuals who met the criteria for Rules 2-4 during a hospital admission prior to the admission during which they were randomised were considered to have prior ESRD provided they did not meet the criteria for Rule 1 after meeting the other criteria.

Rule 1: Kidney Transplantation

Occurrence of any incident kidney transplant code (with no removal within 90 days), or a prevalent kidney transplant code with no removal having occurred prior to the record.

Rule 2: Peritoneal maintenance dialysis

Occurrence of any admission with a peritoneal dialysis code (without diagnosis of acute kidney injury).

Rule 3: Definite maintenance dialysis

Occurrence of a dialysis code in a patient who has had:

- (a) a diagnostic code for ESRD any time prior to, or within 365 days; or
- (b) the insertion of an AV fistula or graft any time prior to, or within 365 days.

Rule 4: Probable maintenance dialysis

The occurrence of at least two episodes containing a dialysis code, with at least 90 days between the start of the first recorded dialysis, and the start of any subsequent dialysis (without diagnosis of acute kidney injury).

Relevant ICD-10 and OPCS-4 codes for Rules 1-4 above

Group	Category	ICD-10	OPCS-4	Description
Diagnosis	Acute kidney injury	N17		Acute renal failure
Diagnosis	End-stage renal disease	N18.0		End-stage renal disease
Diagnosis	End-stage renal disease	N18.5		Chronic kidney disease, stage 5
Diagnosis	End-stage renal disease	Q60.1		Renal agenesis, bilateral
Dialysis	Dialysis	E85.3		Secondary systemic amyloidosis (dialysis related)
Dialysis	Dialysis	Y60.2		Unintentional cut, puncture, perforation or haemorrhage during surgical and medical care; during kidney dialysis.....
Dialysis	Dialysis	Y61.2		Foreign object accidentally left in body during surgical and medical care; during kidney dialysis or other perfusion
Dialysis	Dialysis	Y62.2		Failure of sterile precautions during surgical and medical care; during kidney dialysis or other perfusion
Dialysis	Dialysis	Y84.1		Other medical procedures as the cause of abnormal reaction of the patient, or of later complication; kidney dialysis
Dialysis	Dialysis	Z99.2		Dependence on enabling machines and devices, not elsewhere classified; dependence on renal dialysis
Dialysis	Dialysis		X40.1	Renal dialysis
Dialysis	Haemodialysis	T82.4		Mechanical complication of vascular dialysis catheter
Dialysis	Haemodialysis	Z49.1		Care involving dialysis; extracorporeal dialysis
Dialysis	Haemodialysis		X40.3	Haemodialysis NEC
Dialysis	Haemodialysis		X40.4	Haemofiltration
Dialysis	Insertion of AVF or graft		L74.1	Insertion of arteriovenous prosthesis
Dialysis	Insertion of AVF or graft		L74.2	Creation of arteriovenous fistula NEC
Dialysis	Insertion of AVF or graft		L74.6	Creation of graft fistula for dialysis
Dialysis	Insertion of AVF or graft		L74.8	Other specified arteriovenous shunt
Dialysis	Insertion of AVF or graft		L74.9	Unspecified arteriovenous shunt
Dialysis	Insertion of PD catheter		X41.1	Insertion of ambulatory peritoneal dialysis catheter
Dialysis	Peritoneal dialysis	Z49.2		Care involving dialysis; other dialysis
Dialysis	Peritoneal dialysis		X40.2	Peritoneal dialysis NEC
Dialysis	Peritoneal dialysis		X40.5	Automated peritoneal dialysis
Dialysis	Peritoneal dialysis		X40.6	Continuous ambulatory peritoneal dialysis
Dialysis	Tunnelled line insertion		L91.5	Insertion of tunnelled venous catheter
Transplantation	Incident kidney transplant		M01.2	Allotransplantation of kidney from live donor
Transplantation	Incident kidney transplant		M01.3	Allotransplantation of kidney from cadaver NEC
Transplantation	Incident kidney transplant		M01.4	Allotransplantation of kidney from cadaver heart beating
Transplantation	Incident kidney transplant		M01.5	Allotransplantation of kidney from cadaver heart non-beating
Transplantation	Incident kidney transplant		M01.8	Other specified transplantation of kidney
Transplantation	Incident kidney transplant		M01.9	Unspecified transplantation of kidney
Transplantation	Prevalent kidney transplant	N16.5		Renal tubulo-interstitial disorders in transplant rejection
Transplantation	Prevalent kidney transplant	T86.1		Kidney transplant failure and rejection
Transplantation	Prevalent kidney transplant	Z94.0		Kidney transplant status
Transplantation	Prevalent kidney transplant		M08.4	Exploration of transplanted kidney
Transplantation	Prevalent kidney transplant		M17.4	Post-transplantation of kidney examination - recipient
Transplantation	Prevalent kidney transplant		M17.8	Other specified interventions associated with transplantation of kidney
Transplantation	Prevalent kidney transplant		M17.9	Unspecified interventions associated with transplantation of kidney
Transplantation	Removal of kidney transplant		M02.6	Excision of rejected transplanted kidney

12 Appendix 4: Definitions of discharge and of elective/planned admissions

Definition of discharge used for the time to discharge outcome (see section 6.3)

Dataset	Criteria	Definition
PEDW	Discharge method not died or transfer No other admission up to 4 days before or 1 day after discharge which suggests transfer	Discharge method not 4 or 8, and Discharge destination not 49, 51, 52, 53, 55, 56, 57, 79, 87, 98 Admission source 51 or 87, or Admission method 2B, 81 or 28
HES/SUS	Discharge not died or transfer No other admission up to 4 days before or 1 day after discharge which suggests transfer	Discharge method not 4 or 8, and Discharge destination not 49, 50, 51, 52, 53, 79, 87 or 98 Admission source 51 or 87, or Admission method 2B, 81 or 28
SMR01	Discharge not died or transfer No other admission up to 4 days before or 1 day after discharge which suggests transfer	Discharge type not 40-43, and Discharge type is 10, 11, 18, 19, 70, 20-23, 28, 29 Admission type 18, 30, 36, 38, 39, 40

Definition of planned / elective admissions used for the 6-months outcomes (see section 8.1.1)

Dataset	Admission type	Definitions
PEDW	Planned	If admission method NOT (21 or 22 or 23 or 24 or 25 or 27 or 28 or 81)
HES/SUS	Planned	IF admission method NOT (21 or 22 or 23 or 24 or 25 or 28 or 81 or 2A or 2B or 2C or 2D)
SMR01	Planned	IF admission type NOT (18 or 20 or 21 or 22 or 30 or 31 or 32 or 33 or 34 or 35 or 36 or 38 or 39)

13 Appendix 5: Example hospital recorded diagnoses showing extraction of start and end dates

Table: Four example HESAPC spells each containing three episodes

	Example 1	Example 2	Example 3	Example 4
Episode 1 Episode start date 01/02/2021 Episode end date 02/02/2021	R07.4 Chest pain unspecified	I219 Acute myocardial infarction, unspecified	J18.0 Bronchopneumonia unspecified	N17.9 Acute renal failure unspecified
Episode 2 Episode start date 02/02/2021 Episode end date 05/02/2021	I21.4 Acute subendocardial myocardial infarction	I210 Acute transmural myocardial infarction of anterior wall	J15.9 Bacterial pneumonia unspecified	I26.0 Pulmonary embolism with mention of acute cor pulmonale
Episode 3 Episode start date 05/02/2021 Episode end date 08/02/2021	A04.7 Enterocolitis due to Clostridium difficile	I210 Acute transmural myocardial infarction of anterior wall	J15.2 Pneumonia due to staphylococcus	N17.9 Acute renal failure unspecified

The hospital recorded diagnoses and relevant dates which would be extracted from these examples are as follows:

Example 1:

- R07.4 Start date 01/02/2021 End date 02/02/2021
- I21.4 Start date 02/02/2021 End date 05/02/2021
- A04.7 Start date 05/02/2021 End date 08/02/2021

Example 2:

- I219 Start date 01/02/2021 End date 08/02/2021

Example 3:

- J18.0 Start date 01/02/2021 End date 02/02/2021
- J15.9 Start date 02/02/2021 End date 08/02/2021

Example 4:

- N17.9 Start date 01/02/2021 End date 08/02/2021
- I26.0 Start date 02/02/2021 End date 05/02/2021